Anti-HDAC2 monoclonal antibody
Pre-made anti-HDAC2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to HDAC2/HDAC2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T51191-Ab-1/ GM-Tg-hg-T51191-Ab-2 | Anti-Human HDAC2 monoclonal antibody | Human |
GM-Tg-rg-T51191-Ab-1/ GM-Tg-rg-T51191-Ab-2 | Anti-Rat HDAC2 monoclonal antibody | Rat |
GM-Tg-mg-T51191-Ab-1/ GM-Tg-mg-T51191-Ab-2 | Anti-Mouse HDAC2 monoclonal antibody | Mouse |
GM-Tg-cynog-T51191-Ab-1/ GM-Tg-cynog-T51191-Ab-2 | Anti-Cynomolgus/ Rhesus macaque HDAC2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T51191-Ab-1/ GM-Tg-felg-T51191-Ab-2 | Anti-Feline HDAC2 monoclonal antibody | Feline |
GM-Tg-cang-T51191-Ab-1/ GM-Tg-cang-T51191-Ab-2 | Anti-Canine HDAC2 monoclonal antibody | Canine |
GM-Tg-bovg-T51191-Ab-1/ GM-Tg-bovg-T51191-Ab-2 | Anti-Bovine HDAC2 monoclonal antibody | Bovine |
GM-Tg-equg-T51191-Ab-1/ GM-Tg-equg-T51191-Ab-2 | Anti-Equine HDAC2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T51191-Ab-1/ GM-Tg-hg-T51191-Ab-2; GM-Tg-rg-T51191-Ab-1/ GM-Tg-rg-T51191-Ab-2; GM-Tg-mg-T51191-Ab-1/ GM-Tg-mg-T51191-Ab-2; GM-Tg-cynog-T51191-Ab-1/ GM-Tg-cynog-T51191-Ab-2; GM-Tg-felg-T51191-Ab-1/ GM-Tg-felg-T51191-Ab-2; GM-Tg-cang-T51191-Ab-1/ GM-Tg-cang-T51191-Ab-2; GM-Tg-bovg-T51191-Ab-1/ GM-Tg-bovg-T51191-Ab-2; GM-Tg-equg-T51191-Ab-1/ GM-Tg-equg-T51191-Ab-2 |
Products Name | Anti-HDAC2 monoclonal antibody |
Format | mab |
Target Name | HDAC2 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-HDAC2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T51191-Ag-1 | Recombinant multi-species HDAC2/ HD2/ RPD3 protein |
Target information
Target ID | GM-T51191 |
Target Name | HDAC2 |
Gene ID | 3066,15182,84577,694662,475035,101088165,407223,100072578 |
Gene Symbol and Synonyms | D10Wsu179e,HD2,HDAC2,KDAC2,mRPD3,RPD3,YAF1,Yy1bp |
Uniprot Accession | Q92769 |
Uniprot Entry Name | HDAC2_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | Cancer |
Gene Ensembl | ENSG00000196591 |
Target Classification | Tumor-associated antigen (TAA) |
The target: HDAC2, gene name: HDAC2, also named as HD2, RPD3, YAF1. This gene product belongs to the histone deacetylase family. Histone deacetylases act via the formation of large multiprotein complexes, and are responsible for the deacetylation of lysine residues at the N-terminal regions of core histones (H2A, H2B, H3 and H4). This protein forms transcriptional repressor complexes by associating with many different proteins, including YY1, a mammalian zinc-finger transcription factor. Thus, it plays an important role in transcriptional regulation, cell cycle progression and developmental events. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.